IGA Glomerulonephritis Clinical Trial
Official title:
Autonomic Nervous System (ANS) Analysis According to Different Renal Function Stage in Immunoglobin A (IgA) Nephropathy
The estimation of the cardiovascular risk in the general population must take into account
small renal disturbances, as the microalbuminuria. Conversely certain parameters of the
cardiovascular risk influence the evolution of renal diseases, for example the arterial high
blood pressure.
The measure of the activity of the autonomous nervous system, and especially the
quantification of its variability, is a means to estimate the cardiovascular risk. The
investigators formulate the hypothesis that the variability of the autonomous nervous system
is an additional clinical element for the evaluation of the evolutionary risk of renal
diseases.
The aim of this study is to compare the variability of the autonomous nervous system during
the various evolutionary stages of the renal disease.
The renal disease studied will be IgA nephropathy (IgNA). IgNA is a histologically defined
glomerulonephritis (rela biopsy) by the presence of deposits immunoglobulin A (IgA) in the
renal mesangium (at list 1+) by immunofluorescence.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00004448 -
Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy
|
Phase 2 | |
Completed |
NCT01560052 -
Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)
|
N/A | |
Completed |
NCT00006137 -
Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
|
N/A | |
Completed |
NCT00004305 -
Study of Genetic Anomalies of Complement Related Proteins in Patients With IgA Glomerulonephritis
|
N/A | |
Completed |
NCT01115426 -
Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis
|
Phase 4 |